Stryker (SYK) Stock Forecast & Price Target

$364.60 +7.46 (+2.09%)

(As of 12/20/2024 05:30 PM ET)

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
3

Buy
17

Based on 20 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 3 have given a hold rating, and 17 have given a buy rating for SYK.

Consensus Price Target

$405.80
11.30% Upside

According to the 20 analysts' twelve-month price targets for Stryker, the average price target is $405.80. The highest price target for SYK is $450.00, while the lowest price target for SYK is $360.00. The average price target represents a forecasted upside of 11.30% from the current price of $364.60.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SYK Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)	12 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$405.80	$393.65	$378.58	$315.90
Forecasted Upside	11.30% Upside	2.28% Upside	3.29% Upside	6.19% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Medical Companies	S&P 500
Consensus Rating Score	2.85	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	11.30% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/18/2024	Truist Financial 2 of 5 stars		Boost Target	Hold ➝ Hold	$380.00 ➝ $409.00	+11.04%
12/12/2024	Needham & Company LLC 2 of 5 stars		Boost Target	Buy ➝ Buy	$409.00 ➝ $442.00	+17.58%
12/11/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$411.00 ➝ $450.00	+19.39%
12/11/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$400.00 ➝ $425.00	+11.51%
12/11/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$405.00 ➝ $427.00	+11.66%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
10/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$402.00 ➝ $418.00	+16.11%
10/30/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$383.00 ➝ $394.00	+8.50%
10/30/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$360.00 ➝ $400.00	+11.01%
10/30/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$380.00 ➝ $420.00	+17.04%
10/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$375.00 ➝ $420.00	+16.71%
10/30/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$366.00 ➝ $370.00	+2.61%
10/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$380.00 ➝ $384.00	+6.50%
10/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$378.00 ➝ $405.00	+12.73%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$405.00	+11.64%
7/31/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$375.00 ➝ $365.00	+11.86%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$372.00	+9.06%
5/1/2024	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$348.00 ➝ $405.00	+24.47%
4/11/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$365.00 ➝ $400.00	+15.82%
9/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$310.00 ➝ $315.00	+10.74%
5/25/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $310.00	+13.74%
5/2/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$260.00 ➝ $292.00	-0.78%
5/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $345.00	+15.04%
4/23/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$275.00 ➝ $336.00	+10.69%
4/17/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$290.00 ➝ $312.00	+6.94%
1/25/2023	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Weight ➝ Sector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:42 PM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

Stryker Co. recently reported earnings per share (EPS) of $2.87, exceeding analysts' expectations of $2.77, indicating strong financial performance and effective management.
The company has shown a year-over-year revenue increase of 11.9%, reaching $5.49 billion, which reflects robust growth and demand for its medical technology products.
With a current stock price around $370.18, Stryker Co. is positioned well within its 52-week range, suggesting potential for appreciation as it approaches its 52-week high of $398.20.
Stryker Co. has a solid dividend yield of 0.88%, which can provide investors with a steady income stream, especially appealing in a low-interest-rate environment.
The company maintains a healthy debt-to-equity ratio of 0.66, indicating a balanced approach to leveraging debt for growth while minimizing financial risk.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

The stock has a relatively high price-to-earnings (P/E) ratio of 41.77, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
Despite recent growth, the company's beta of 0.94 indicates that it is less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
The dividend payout ratio (DPR) is at 34.30%, which, while sustainable, may limit the company's ability to reinvest profits into growth initiatives.
Analysts have mixed ratings, with four holding and seventeen giving buy ratings, indicating some uncertainty in market sentiment regarding the stock's future performance.
Recent target price adjustments by analysts suggest a cautious outlook, with some raising their targets but still reflecting a range that may not excite aggressive investors.

SYK Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $405.80, with a high forecast of $450.00 and a low forecast of $360.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYK shares.
: According to analysts, Stryker's stock has a predicted upside of 11.30% based on their 12-month stock forecasts.
: Over the previous 90 days, Stryker's stock had 1 upgrade by analysts.
: Stryker has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Stryker more than other "medical" companies. The consensus rating score for Stryker is 2.85 while the average consensus rating score for "medical" companies is 2.81. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

This page (NYSE:SYK) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target